Genmab's petosemtamab-pembrolizumab combination achieves 28.2-month median survival in Phase 2 head and neck cancer trial

• Genmab reported updated Phase 2 results showing durable responses with petosemtamab combined with pembrolizumab in first-line recurrent or metastatic head and neck cancer.
• Responses occurred across patient subgroups, including HPV-positive and HPV-negative disease.
• No treatment-related deaths were reported; all infusion-related reactions resolved.
• Results were presented at the European Society for Medical Oncology Congress 2026 in Madrid.
• The petosemtamab development program includes four Phase 3 trials across head and neck cancer and colorectal cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023679277) on October 26, 2026, and is solely responsible for the information contained therein.